Zanubrutinib Clinical Trials
46 recruitingDrug
Phase 232Phase 18Phase 35Phase 42
Showing 1–20 of 46 trials
Recruiting
Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled125 locationsNCT04840602
Recruiting
Phase 3
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology421 enrolled233 locationsNCT05976763
Recruiting
Phase 2
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Chronic Lymphocytic LeukemiaB-cell Malignancies
Curis, Inc.108 enrolled3 locationsNCT07271667
Recruiting
Phase 2
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Waldenstrom Macroglobulinemia
Massachusetts General Hospital55 enrolled5 locationsNCT06561347
Recruiting
Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center230 enrolled8 locationsNCT03824483
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled49 locationsNCT06634589
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
BeOne Medicines500 enrolled14 locationsNCT07277231
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Mantle Cell Lymphoma
BeOne Medicines300 enrolled149 locationsNCT06742996
Recruiting
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Waldenstrom Macroglobulinemia
BeiGene111 enrolled8 locationsNCT05640102
Recruiting
Phase 2
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Refractory CancerPrimary Central Nervous System LymphomaRelapsed Cancer+1 more
Baptist Health South Florida15 enrolled1 locationNCT05681195
Recruiting
Phase 2
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma+5 more
Aseel Alsouqi24 enrolled3 locationsNCT05873712
Recruiting
Phase 2
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
LymphomaMantle Cell Lymphoma
Christine Ryan60 enrolled7 locationsNCT06854003
Recruiting
Phase 2
Epco, Zanu, Ritux for R/R FL or MZL
Non-Hodgkin LymphomaLymphomaFollicular Lymphoma+3 more
Reid Merryman, MD45 enrolled3 locationsNCT06563596
Recruiting
Phase 3
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.394 enrolled2 locationsNCT07377578
Recruiting
Phase 2
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Follicular LymphomaMarginal Zone Lymphoma
H. Lee Moffitt Cancer Center and Research Institute43 enrolled1 locationNCT06350318
Recruiting
Phase 2
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Virginia Commonwealth University21 enrolled1 locationNCT06846463
Recruiting
Phase 2
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Lymphoma
M.D. Anderson Cancer Center36 enrolled1 locationNCT06563505
Recruiting
Phase 2
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Sun Yat-sen University42 enrolled1 locationNCT06647732
Recruiting
Phase 2
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
LymphomaFollicular Lymphoma
Memorial Sloan Kettering Cancer Center152 enrolled9 locationsNCT05389293